While West Virginia's employee health insurance program covers drugs like Ozempic for people with type 2 diabetes, officials ...

Trump could keep Biden’s commitment to have Medicare pay for weight loss drugs such as Ozempic and Wegovy. But would ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Higher-income households with at least one user of GLP-1 class of weight loss drugs cut their grocery spending by nearly 9%, ...

Right now, Novo stock is trading at a forward price-to-earnings (P/E) multiple of 22.5 -- its lowest level in well over a year. I think now is a terrific opportunity to scoop up shares of Novo on the ...

Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...

Wegovy and Ozempic are weight loss drugs that promise to transform the treatment of obesity, heart disease and other chronic conditions that afflict millions of Americans. But while everyone agrees ...

According to the study, participants taking Zepbound lost an average of 20.2% of their starting weight after 72 weeks, ...

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...